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During pathologic vessel remodeling, vascular smooth muscle cells (VSMCs) embedded 
within the collagen-rich matrix of the artery wall mobilize uncharacterized proteolytic 
systems to infiltrate the subendothelial space and generate neointimal lesions. Although the 
VSMC-derived serine proteinases, plasminogen activator and plasminogen, the cysteine 
proteinases, cathepsins L, S, and K, and the matrix metalloproteinases MMP-2 and MMP-9 
have each been linked to pathologic matrix-remodeling states in vitro and in vivo
 
,
 
 the role 
that these or other proteinases play in allowing VSMCs to negotiate the three-dimensional 
(3-D) cross-linked extracellular matrix of the arterial wall remains undefined. Herein, we 
demonstrate that VSMCs proteolytically remodel and invade collagenous barriers 
independently of plasmin, cathepsins L, S, or K, MMP-2, or MMP-9. Instead, we identify the 
membrane-anchored matrix metalloproteinase, MT1-MMP, as the key pericellular 
collagenolysin that controls the ability of VSMCs to degrade and infiltrate 3-D barriers of 
interstitial collagen, including the arterial wall. Furthermore, genetic deletion of the 
proteinase affords mice with a protected status against neointimal hyperplasia and lumen 
narrowing in vivo. These studies suggest that therapeutic interventions designed to target 
MT1-MMP could prove beneficial in a range of human vascular disease states associated 
with the destructive remodeling of the vessel wall extracellular matrix.
 
In disease states ranging from atherosclerosis to
postangioplasty restenosis, vascular smooth
muscle cells (VSMCs) embedded in a dense,
three-dimensional (3-D) matrix of interstitial
collagens activate a tissue-invasive program
that supports migration from the vessel wall
media into the subendothelial intimal space
(1). Within this compartment, smooth muscle
cells proliferate and deposit extracellular matrix
molecules, ultimately leading to the formation
of neointimal lesions that can occlude the arterial
lumen directly or precipitate catastrophic occlu-
sive events by triggering thrombosis (1, 2).
Although proteolytic enzymes are assumed to
play a critical role in conferring VSMCs with
the ability to traverse the type I collagen–rich
media of the arterial wall (3–14), the identity
of the matrix-degrading proteinases that confer
tissue-invasive activity have remained the sub-
ject of speculation.
To date, efforts to characterize the matrix
remodeling activities of VSMCs have empha-
sized potential roles for the serine proteinases,
plasminogen activator and plasminogen, the
cysteine proteinases, cathepsins K, L, and S, or
the matrix metalloproteinases (MMPs) MMP-2
and MMP-9 (3–14). However, which, if any,
of these proteinases participate directly in the
collagen-degradative events necessary to drive
VSMC invasion through 3-D matrix barriers is
unknown. Herein, we demonstrate that VSMCs
mobilize a pericellular proteolytic activity that
allows them to degrade and invade collagen-
rich tissues in 3-D explants via a process that
operates independently of the plasminogen
activator–plasminogen axis, cysteine protein-
 
The online version of this article contains supplemental material.
 
CORRESPONDENCE
Stephen J. Weiss:
sjweiss@umich.edu
 
Abbreviations used: 2-D, two-
dimensional; 3-D, three-
dimensional; BrdU, bromode-
oxyuridine; FGF, fibroblast 
growth factor; MMP, matrix 
metalloproteinase; MT1, mem-
brane type I; PCNA, proliferat-
ing cell nuclear antigen; PDGF, 
platelet-derived growth factor; 
TIMP, tissue inhibitor of metallo-
proteinases; VSMC, vascular 
smooth muscle cell. 
REGULATION OF SMOOTH MUSCLE CELL INVASION | Filippov et al.
 
664
 
ases, MMP-2, or MMP-9. Instead, VSMCs rely on the peri-
cellular collagenase, membrane type I (MT1)-MMP, to infil-
trate 3-D barriers of type I collagen, composites of type I and
III collagen, or the arterial wall itself. Further, using MT1-
MMP
 
 
 
/
 
 
 
 heterozygote mice, we demonstrate that even a
partial reduction in MT1-MMP expression levels amelio-
rates the vessel wall damage and remodeling associated with
pathologic VSMC invasion in vivo.
 
RESULTS
 
In pathologic states in vivo
 
,
 
 medial VSMCs gain access to
the subintimal space by expressing motile activity within the
confines of the 3-D matrix largely comprised of type I col-
lagen (1, 15). Although most in vitro analyses of VSMC
function have been performed under two-dimensional (2-D)
culture conditions wherein cells are plated atop a matrix sub-
stratum (3–14), recent studies indicate that mesenchymal cell
phenotype is altered significantly when cells are embedded
within, rather than cultured atop, a 3-D extracellular matrix
(16, 17). Hence, to recapitulate the collagen-rich, 3-D inter-
stitial matrix confronted by VSMCs exposed to invasion-
promoting growth factors in situ
 
,
 
 medial explants recovered
from WT mice were embedded within a cross-linked matrix
of type I collagen (Fig. 1 a). The transition of VSMCs from a
quiescent contractile state to a proliferating invasive pheno-
type was triggered by the addition of autologous serum sup-
plemented with platelet-derived growth factor (PDGF)-BB
and fibroblast growth factor 2 (FGF-2; PDGF/FGF-2) (18).
After a 3-d lag, VSMCs begin to emigrate from the tissue
explant and to infiltrate the surrounding type I collagen ma-
trix (Fig. 1 b). By 8 d, a dense cloud of VSMCs surround the
explant, with the leading front of the advancing cells having
traversed 
 
 
 
1,000 
 
 
 
m of dense collagen (Fig. 1 c). The tis-
sue-invasive VSMCs acquire a spindle cell–like morphology
as they negotiate the surrounding 3-D matrix while leaving
tunnels of immunodetectable collagen degradation products
in their wake (Fig. 1, d and f).
VSMCs, like other mesenchymal cell populations, can mo-
bilize multiple proteolytic systems to degrade and migrate
through collagenous barriers (3–14). To identify the major
proteinase classes involved in regulating 3-D invasion, explants
were embedded in collagen gels in the presence of inhibitors
directed against cysteine-, aspartyl-, serine-, or metalloprotein-
ases (8, 19–21), and migratory responses were monitored over
the course of an 8-d incubation period. At concentrations pre-
viously demonstrated to block cysteine proteinase or aspartyl
proteinase activity effectively (8, 19–21), neither E-64 nor pep-
statin A affect VSMC invasion (Fig. 1, g, h, and p). Further,
VSMC emigration proceeds in an unabated fashion either in
 
Figure 1. Ex vivo invasive activity of VSMCs in 3-D collagen. 
 
(a–c) Media explants of mouse aorta were embedded within a 3-D gel of 
type I collagen, VSMC egress was initiated by exogenous PDGF/FGF-2, and 
outgrowth into the translucent collagen matrix was visualized by darkfield 
microscopy at 0, 3, and 8 d. Asterisk indicates explant , and arrowheads 
point at the leading edge of the invading SMC. Bar, 1 mm. Inset in (a) shows 
anti-SM 
 
 
 
-actin staining (brown) of the media explant. (d and e) Scanning 
electron micrograph of freeze-fractured explant cultures. Asterisks mark 
invading VSMCs that have infiltrated into the field of densely packed type 
I collagen fibrils. Arrows highlight VSMC cytoplasmic extensions. Tunnels 
(star) in the collagen matrix are seen in areas surrounding the embedded 
explant. Bar, 20 
 
 
 
m. (f) Degraded collagen (detected by mAb HUI77) appears 
as punctate green staining (arrows) surrounding propidium iodide–labeled 
cells (red, asterisks). Bar, 20 
 
 
 
m. (g–o) Media explants from WT, plasmino-
gen (plg)-, MMP-9–, or MMP-2–null mice were suspended in collagen in 
autologous sera and cultured for 8 d in the absence or presence of E-64, 
pepstatin, aprotinin, BB-94, TIMP-1, or TIMP-2 as described in Materials and 
methods. Insets in j, k, n, and o show immunostains for degraded collagen 
(mAb HUI77) surrounding propidium iodide–labeled cells. Bar, 1 mm. (p) 
Quantitative analysis of VSMC invasive activity in aortic explant 
cultures after an 8-d culture period. Results are expressed as the mean 
 
 
 
 
SEM (
 
n
 
 
 
 
 
 5).  
JEM VOL. 202, September 5, 2005
 
665
 
ARTICLE
 
the presence of the plasmin inhibitor aprotinin (19, 20) or
when explants are recovered from plasminogen-null mice and
suspended in plasminogen-null serum (Fig. 1, i, j, and p). In
contrast, both the tissue-invasive activity expressed by VSMC
outgrowth and VSMC collagen-degradative activity are ab-
lated by the MMP inhibitor BB-94 (Fig. 1, k and p).
MMPs currently are classified as a family of more than 20
proteinases whose members are expressed either as secreted or
membrane-anchored enzymes (22). The endogenous tissue
inhibitor of metalloproteinases (TIMP-1), preferentially tar-
gets secreted MMPs as well as the glycophosphatidylinositol-
anchored MMPs (i.e., MT4-MMP and MT6-MMP) (22–
24). A second member of the TIMP family, TIMP-2, more
potently inhibits secreted MMPs, MMP-2, and MMP-9, as
well as the type I membrane–anchored MMPs (i.e., MT1-, 2-,
3-, and 5-MMPs) (22–24). Although VSMC invasion is unaf-
fected by TIMP-1 (Fig. 1, l and p), equimolar concentrations
of active TIMP-2 exerted an inhibitory effect indistinguish-
able from that observed with BB-94 (Fig. 1, m and p).
Recently, a series of studies have concluded that MMP-2
and MMP-9 play key roles in regulating the 2-D migration
of VSMCs (3–5, 9–14). However, although both MMP-2
and MMP-9 are preferentially inhibited by TIMP-2 (23
 
),
 
VSMC outgrowth from either collagen-embedded MMP-
2
 
 
 
/
 
 
 
 or MMP-9
 
 
 
/
 
 
 
 explants cultured, respectively, in
MMP-2
 
 
 
/
 
 
 
 or MMP-9
 
 
 
/
 
 
 
 autologous serum proceeds in a
fashion indistinguishable from littermate controls (Fig. 1,
n–p). Likewise, neither of the KO explants displayed out-
growth defects when embedded in a 3-D matrix of Matrigel
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20050607/DC1). Hence, MMP-2 and MMP-9 are not
necessary in regulating the tissue-invasive machinery mobi-
lized by smooth muscle cells during 3-D invasion.
Although the ability of TIMP-2 to block VSMC inva-
sion cannot be ascribed to inhibitory effects on either MMP-2
or MMP-9, at least two TIMP-2–sensitive members of the
membrane-anchored MMP family, i.e., MT1-MMP and
MT2-MMP, have been described recently as potent col-
lagenolysins (19, 25–28). Because WT explants express only
MT1-MMP and MT3-MMP (Fig. 2 a), and MT3-MMP
does not express type I collagenolytic activity (25, 26, 28,
29), we next determined the collagen-invasive potential of
explants recovered from MT1-MMP–null mice (30). Al-
though MT1-MMP–null VSMCs express MMP-2, MMP-9,
Figure 2. MT1-MMP–dependent control of VSMC invasion. 
(a and b) Media explants from MT1-MMP /  and MT1-MMP /  mice were 
suspended within 3-D gels of type I collagen, a mixture of type I and III 
collagens, fibrin, or Matrigel. Asterisks indicate the position of the explants, 
and arrowheads mark the leading edge of egressing VSMC. Bars, 1 mm. 
Upper right panels show RT-PCR analysis of MMPs expressed by invading 
VSMCs. (c and d) Semi-thin sections (upper left panels) and transmission 
electron micrographs (right side-panels) of media explant (stars) cultured 
within 3-D collagen matrix for 8 d. (c) Zones of degraded collagen lie jux-
taposed to the WT VSMCs as assessed by staining for denatured collagen 
(green staining, arrows) around propidium iodide–labeled cells (red, asterisk) 
or by areas of collagen clearing in transmission electron micrographs. 
(d) Intact collagen fibrils lie adjacent to MT1-MMP /  VSMCs. Bars, 20  m 
for two left panels and 2  m for right panel. 
REGULATION OF SMOOTH MUSCLE CELL INVASION | Filippov et al.
 
666
 
and MMP-13 as well as MT3-MMP mRNA at compara-
ble levels, MT1-MMP
 
 
 
/
 
 
 
 explants fail to display invasive
activity either in 3-D matrices of type I collagen or in a
composite gel of type I and III collagens (Fig. 2, a and b).
Further, in contrast with the behavior of WT VSMCs,
MT1-MMP
 
 
 
/
 
 
 
 VSMCs are confined to the interface be-
tween the explant surface and the surrounding matrix; col-
lagen-degradation products are not detected in association
with the immobile cells (Fig. 2, c and d). In electron micro-
graphs of the explant cultures, WT VSMCs are surrounded
by collagen-free zones generated as a consequence of peri-
cellular collagenolysis, but intact collagen fibrils are consis-
tently found in juxtaposition to the surface of MT1-MMP
 
 
 
/
 
 
 
VSMC (Fig. 2, c and d). Importantly, the invasion-null
phenotype is confined to interstitial collagen barriers because
MT1-MMP
 
 
 
/
 
 
 
 VSMCs readily traverse a 3-D gel of cross-
linked fibrin, a physiologically relevant matrix whose pro-
teolysis is supported equally well by either MT1-MMP or
MT3-MMP (Fig. 2, a and b; [29]). Likewise, MT1-MMP–
null VSMC traverse dense matrices of Matrigel, a basement
membrane extract whose remodeling proceeds indepen-
dently of MT1-MMP (Fig. 2, a and b), MMP-2, or MMP-9
(unpublished data; [19, 25, 29]).
To determine if defects in collagenolysis and invasive ac-
tivity can be ascribed directly to isolated VSMCs, smooth
muscle cells were recovered from MT1-MMP
 
 
 
/
 
 
 
 or MT1-
MMP
 
 
 
/
 
 
 
 explants and were cultured atop a subjacent bed of
type I collagen fibrils. Under these conditions, WT but not
MT1-MMP
 
 
 
/
 
 
 
 VSMCs express collagenolytic activity and
invade type I collagen gels (Fig. 3, a and b). The inability of
Figure 3. Collagenolytic activity of isolated MT1-MMP /  VSMCs. 
(a) Isolated WT cells, MT1-MMP-null VSMCs, or MT1-MMP–transduced 
null cells (rMT1-MMP) were cultured atop a film of type I collagen (upper 
row) or a 3-D gel of type I collagen (middle row) in the absence or presence 
of BB-94. Upper row: yellow arrowheads mark zones of collagen proteolysis. 
Insets are phase contrast micrographs of MT1-MMP /  and MT1-MMP /  
VSMCs that were cultured atop the collagen film substratum. Middle row: 
black arrows indicate the position of VSMCs that have invaded the collagen 
gels. Bottom row: fluorescently labeled VSMCs (green) were cultured atop 
devitalized aorta. White arrowheads mark the position of VSMCs that 
invaded the aortic tissue. Bars, 50  m. (b) Quantitative analysis of the 
MT1-MMP–dependent collagenolytic and invasive activities displayed by 
smooth muscle cells cultured as described. Results are expressed as the 
mean   SEM (n   5). (c) VSMC proliferation (BrdU) and apoptosis (TUNEL) 
in WT and MT1-MMP /  cultures established atop type I collagen gels. 
TUNEL-positive VSMCs (arrowheads) and BrdU-labeled VSMCs (arrows) are 
shown with propidium iodide counterstaining (red) used to visualize cells. 
Bar, 50  m. Right panels: motility of MT1-MMP /  and MT1-MMP /  
VSMCs across a type I collagen–coated substratum. The dashed yellow 
line marks the position of cells at the start of the assay; the red arrow 
indicates the position of the leading front of cells after 72 h in culture. 
Bar, 0.5 mm. 
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MT1-MMP
 
 
 
/
 
 
 
 VSMC to negotiate 3-D collagen gels is not
limited to in vitro ECM constructs, because these findings
could be extended to the vessel wall itself. Whereas WT flu-
orescent-tagged VSMCs invade explants of devitalized aorta,
MT1-MMP
 
 
 
/
 
 
 
 VSMCs remain confined to the surface of
the vessel wall (Fig. 3 a, lower row). After reconstitution of
MT1-MMP expression in MT1-MMP
 
 
 
/
 
 
 
 VSMCs by retro-
viral transduction, the null cells fully recover the ability to
degrade subjacent collagen and to invade either the reconsti-
tuted collagen matrices or the vessel wall explants (Fig. 3, a
and b). Despite obvious defects in the ability of MT1-
MMP
 
 
 
/
 
 
 
 VSMCs to remodel collagen or to invade col-
lagen-rich tissues, rates of proliferation, apoptosis, and 2-D
migration across collagen-coated surfaces are indistinguish-
able from littermate controls (Fig. 3 c).
In humans, the intima-media thickening that occurs as a
consequence of VSMC migration and proliferation within
the carotid artery is an important predictive phenotype for
cardiovascular disease (1, 2, 31). Because elevated MT1-
MMP expression has been localized at pathologic sites of
vascular remodeling in vivo (32, 33
 
),
 
 we next sought to de-
termine whether an MT1-MMP–deficient status would af-
fect VSMC behavior in vivo during neointima formation.
Although the morbid status and decreased lifespan of MT1-
MMP
 
 
 
/
 
 
 
 mice complicate the use of the homozygote-null
animals (30), pilot experiments were initiated in an attempt
to gauge the response of the null animals to the surgical pro-
cedure. However, none of the MT1-MMP
 
 
 
/
 
 
 
 mice recov-
ered from even a brief period of anesthesia (
 
n
 
 
 
 
 
 4). Hence,
the phenotypically normal heterozygotes were selected for
further study because the isolated cells displayed an 
 
 
 
25%
reduction in collagen-invasive activity in vitro (unpublished
data). Hence, MT1-MMP
 
 
 
/
 
 
 
 and MT1-MMP
 
 
 
/
 
 
 
 litter-
mates underwent unilateral common carotid artery ligation
to induce neointima formation via a hemodynamically initi-
ated process that involves minimal endothelial cell damage
or inflammation (34). The total number of cells that migrate
into the subendothelial space during the first 5 d after liga-
tion is strikingly reduced in heterozygous arteries (Fig. 4, a
and d). Further, at day 14 after ligation, MT1-MMP haplo-
insufficient mice remain protected against occlusive vascular
remodeling (Fig. 4, a and d). At 2 wk after surgery, the li-
gated arteries of MT1-MMP
 
 
 
/
 
 
 
 mice display marked neoin-
timal hyperplasia and outward geometric remodeling accom-
panied by local increases in MMP-2 and MMP-9 expression
(Fig. 4, a and b [12, 13]). By contrast, in the ligated carotids
of MT1-MMP
 
 
 
/
 
 
 
 mice, neointimal size and cell number, as
well as the intima/media ratios, are reduced by 
 
 
 
50% de-
spite similar, if not enhanced, increases in MMP-2 and
MMP-9 expression (Fig. 4, a and b). Intimal thickening is
not detected in the contralateral carotids of either genotype
(Fig. 4 a, insets).
Consistent with a specific role for MT1-MMP in regu-
lating VSMC invasion alone, neither cell replication nor ap-
optotic rates were altered at day 5 (17 
 
 
 
 1 versus 16 
 
 
 
 2
proliferating cell nuclear antigen [PCNA]-positive cells/
vessel cross section in MT1-MMP
 
 
 
/
 
 
 
 and MT1-MMP
 
 
 
/
 
 
 
mice, respectively, and 24 
 
 
 
 1 versus 24 
 
 
 
 3 TUNEL-posi-
tive cells/vessel cross section in MT1-MMP
 
 
 
/
 
 
 
 and MT1-
MMP
 
 
 
/
 
 
 
 mice, respectively) or at day 14 after ligation in
MT1-MMP heterozygote mice (Fig. 4, c and d). Likewise,
no differences in rates of macrophage influx were detected
between MT1-MMP
 
 
 
/
 
 
 
 and MT1-MMP
 
 
 
/
 
 
 
 mice (unpub-
lished data). Interestingly, although intimal size is decreased
significantly in the heterozygote mice, the ligated vessel un-
dergoes compensatory outward remodeling to a degree simi-
lar to that exhibited by the WT animals (as assessed by length
of the external elastic lamina) coincident with indistinguish-
able rates of collagen deposition in the remodeling vessels
(Fig. 4, c and d). Consequently, and in marked contrast to
the response of the ligated MT1-MMP
 
 
 
/
 
 
 
 carotids, a reduc-
tion in intimal expansion in MT1-MMP
 
 
 
/
 
 
 
 mice is coupled
with active outward geometric remodeling that results in an
almost complete retention of the lumen diameter relative to
unmanipulated controls (i.e., whereas lumen diameter de-
creases by 
 
 
 
50% in MT1-MMP
 
 
 
/
 
  ligated carotids, lumen
size remains intact in MT1-MMP /  mice; Fig. 4 d).
Hence, a partial reduction in MT1-MMP expression pro-
tects heterozygote mice against neointimal hyperplasia and
arterial lumen narrowing.
DISCUSSION
A wide range of pathologic insults to the arterial wall induces
VSMCs to infiltrate the intimal space and mount a hyperplas-
tic response that narrows the artery lumen and alters vessel
wall geometry (1–14). Multiple proteolytic systems have been
posited to participate in VSMC migration or invasion (3–14),
but prior studies have focused on assessing the behavior of
passaged VSMCs cultured atop 2-D substrata in short-term
assays that do not recapitulate the 3-D matrix environment in
which the cells are embedded normally (1, 16, 17). In our
studies designed specifically to recapitulate the in vivo envi-
ronment, proteinases linked previously to VSMC migration,
including plasmin, cysteine proteinases, MMP-2, and MMP-9,
do not play a critical role in supporting the 3-D invasive
phenotype. Instead, MT1-MMP confers VSMCs with the
ability to degrade and invade either a composite extracellular
matrix of purified type I and III collagens or the vessel wall it-
self. Although recent studies demonstrate that MT1-MMP / 
VSMCs exhibit a stimulus-specific defect in PDGF-BB–
mediated signaling under serum-free conditions (35), the
ability of the null cells to respond to a mixture of PDGF-BB
and FGF-2 in a serum milieu is unperturbed with regard to
2-D motility and proliferation. Further, MT1-MMP / 
VSMCs do not display a global defect in their ability to
mount invasive responses, because migration through 3-D
barriers of fibrin or Matrigel were unaffected. Rather, MT1-
MMP seems primarily to regulate invasion through type I/III
collagen–rich barriers regardless of the initiating stimulus. We
do note that mouse and human VSMCs can display distinctREGULATION OF SMOOTH MUSCLE CELL INVASION | Filippov et al. 668
Figure 4. MT1-MMP deficiency reduces neointima formation in 
vivo. (a) Verhoeff Van Gieson’s staining of unmanipulated controls as well 
as contralateral and ligated common carotid arteries from MT1-MMP /  
and MT1-MMP /  mice 5 d and 14 d after ligation. Elastic fibers are 
stained black; nuclei are stained brown. Bottom row insets demonstrate 
intact intima in contralateral carotids of either genotype. *, vessel lumen; 
A, adventitia; I, intima; M, media. (b) Gelatin zymography of carotid artery 
extracts 14 d after ligation. The pro- (open arrowheads) and processed 
(arrows) forms of MMP-9 (upper arrowhead and arrow) and MMP-2 (lower 
arrowhead and arrow) are indicated. C, contralateral artery; Lg, ligated 
artery. (c) 14 d after ligation, paraffin sections of ligated carotid arteries 
were probed with anti-smooth muscle  -actin polyclonal antibody ( -actin; 
brown stain) or stained with Picro-Sirius red (PSR; red stain). Cell prolifer-
ation and apoptosis were determined with anti-PCNA mAb (PCNA) and 
TUNEL, respectively. PCNA-positive nuclei (brown, arrows) and TUNEL-
positive cells (arrowheads) are shown. (d) Quantitative assessment of 
vascular remodeling. Charts show individual numbers (six for each group) 
with the mean indicated by a red bar   SEM. All data were obtained at 
day 14 after ligation except for total cell numbers, for which values are 
shown for both days 5 and 14. EEL, external elastic lumina. Bars, 100  m.JEM VOL. 202, September 5, 2005 669
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properties (1, 2), but preliminary studies indicate that MT1-
MMP likewise regulates the collagen-invasive activity of hu-
man aortic smooth muscle cells (unpublished observation).
Although recent studies have suggested that mesenchymal
cells may mobilize nonproteolytic systems to infiltrate con-
nective tissue barriers (36), no compensatory mechanisms
were identified that proved able to rescue the null phenotype
of the invasion-incompetent MT1-MMP /  VSMCs.
MT1-MMP /  mice are runted, infertile, and have a
shortened lifespan, whereas the heterozygote mice exhibit a
normal phenotype (30). Further, in contrast with MT1-
MMP–null mice that harbor defects in endothelial cell–
mural cell interactions as a consequence of a specific defect in
PDGF-BB signaling, the vasculature of the heterozygotes is
normal, and PDGF-BB (35) responses are indistinguishable
from those in WT mice. Hence, the MT1-MMP /  mice
afforded the opportunity to assess the role of the proteinase
in the in vivo setting. Consistent with our ex vivo findings
that highlight the importance of MT1-MMP in conferring
VSMCs with collagenolytic and invasive activities, an MT1-
MMP /  status confers mice with a resistant phenotype
against ligation-induced neointimal hyperplasia. Although
others have reported that MMP-2 /  or MMP-9 /  mice
also exhibit a protected status in this model and have con-
cluded that these enzymes control invasive activity (11–14),
our findings suggest that these proteinases do not play direct
or necessary roles in regulating VSMC migration. Instead,
we posit that MMP-2 and MMP-9 more likely affect the
activity or availability of cell- or matrix-bound growth fac-
tor/growth factor receptors, chemokines, or cytokines (37).
Because both MMP-2– and MMP-9–null mice also suffer
from a number of developmental defects that can affect
events ranging from the mobilization of progenitor cells to
immune function (38–40), the direct or indirect mecha-
nisms by which these metalloenzymes affect neointimal hy-
perplasia deserve further study. These issues notwithstand-
ing, MT1-MMP controls VSMC invasive activity in vitro
and in vivo independently of MMP-2 or MMP-9 activity.
Further, the ability of MT1-MMP, rather than MMP-2 or
MMP-9, to regulate the collagen-degradative and invasive
activities of VSMCs is consistent with more recent studies
of angiogenesis and with fibroblast–extracellular matrix in-
teractions (19, 26, 41–43).
Increasing evidence suggests that the intimal hyperplasia
probably is not restricted to the participation of VSMCs
alone and may involve adventitial fibroblasts, marrow-
derived smooth muscle precursors, or macrophages (1, 2, 44).
Because MT1-MMP may serve as the dominant determinant
of cellular motility within collagen-rich environments, this
proteinase may well play similar roles in regulating the inva-
sive properties of multiple cell types within the context of
the arterial matrix. Given that even a partial reduction in
MT1-MMP expression affords the vessel wall lumen of het-
erozygote animals with a protected status in vivo, therapeu-
tic interventions directed against this proteinase may prove
beneficial in human vascular disease states.
MATERIALS AND METHODS
Mice. All ex vivo and in vivo studies were performed with 4- to 6-wk-old
male plasminogen /  C57BL6 mice (7), MMP-2 /  C57BL6 mice (13),
MMP-9 /  129SvEv mice (12), or MT1-MMP /  or MT1-MMP / 
Swiss Black mice (30). Age-matched C57BL6 animals were used as controls
for plasminogen /  and MMP-2 /  mice, and 129SvEv animals were used
as controls for MMP-9 /  mice. For studies of MT1-MMP /  or MT1-
MMP /  mice, paired analyses were performed with WT littermates.
3-D culture conditions and invasion assays. For 3-D ex vivo inva-
sion assay, type I collagen (acid extracted from rat tail tendons [25]) or type
III collagen (Sigma-Aldrich) was dissolved in 0.2% acetic acid to a final
concentration of 2.7 mg/ml (25). Before assay, fragments of mouse tho-
racic aorta were stripped of intima and adventitia, and the media of the
vessel wall was dissected into 1   1–mm fragments. Media explants were
then suspended within a solution of type I collagen alone, a composite of
type I/type III collagens (3:1), 12 mg/ml Matrigel (Becton Dickinson), or
3 mg/ml cross-linked fibrin prepared as described (25, 29) and were cul-
tured for 8 d in DMEM medium supplemented with 10% FBS, autologous
plasminogen-, MMP-9–, or MMP-2–null mouse sera. A PDGF-BB/FGF-2
mixture (10 ng/ml each; R&D Systems) was added to explant cultures to
initiate VSMC outgrowth and invasion. Invasive activity was quantified by
measuring the distance migrated by the leading front of VSMCs from the
explanted tissue.
To assess the invasive activity of isolated VSMCs, homogeneous cultures
were established from collagenase type 2 (1.5 mg/ml; Worthington Biochem-
ical Corporation) digests of vessel wall explants as described (16). VSMCs
were seeded atop 3-D gels of type I collagen or fibrin in the upper well of 24-
mm Transwell dishes (3- m pore size; Corning, Inc.). After a 24-h incuba-
tion period, a PDGF/FGF-2 mixture was added to the lower compartment of
the Transwell chambers. The number of invasive foci was determined in ran-
domly selected fields by phase-contrast microscopy.
Where indicated, protease inhibitors were added to media explants or
isolated VSMCs at the following final concentrations: 3  M BB-94 (in
0.1% DMSO final; gift of British Biotechnology Ltd.), 5  g/ml TIMP-2,
12.5  g/ml TIMP-1 (equimolar as determined by active site titration [25];
endotoxin-free; Fuji Industries Co., Ltd.), 100  M E-64 (in 0.05% ethanol
final, Sigma-Aldrich), 100  g/ml aprotinin (Roche), or 50  M pepstatin
(in 0.05% ethanol final; Roche).
VSMCs labeled with fluorescent microspheres (Fluoresbrite, Poly-
sciences, Inc.; [19]) were seeded atop segments of dog aorta that had been
devitalized after three rounds of freezing in liquid N2 and thawing. The co-
cultures were suspended in DMEM/10% FCS in the absence or presence of
3  m BB-94 and placed into the upper compartment of 24-mm Transwell
dishes. PDGF/FGF-2 (10 ng each) was added to the lower compartment of
the dishes to initiate invasion.
Retroviral-gene transfer. Hemagglutinin-tagged human MT1-MMP
cDNA was subcloned into the pRET2 retroviral vector derived from the
Moloney murine leukemia virus–based MFG backbone, and polyclonal
ecotropic producer cell lines were established as described (26). Subconflu-
ent monolayers of the isolated VSMCs were cultured in the retroviral su-
pernatant for 12 h, and collagen invasion and degradation assays were per-
formed 24 h later.
RT PCR analysis. RNA was isolated from MT1-MMP WT or null ex-
plant cultures using TRIzol reagent (Life Technologies). RT and PCR am-
plification using specific oligonucleotide primers for MMP-9, MMP-2,
MMP-8, MMP-13, mCol A, MT1-MMP, MT2-MMP, or MT3-MMP
was performed as described (19, 29).
Transmission and scanning electron microscopy.  3-D cultures of
primary aortic media explants were prepared for transmission and scanning
electron microscopy as described previously (25, 29). For freeze-fracture scan-
ning electron microscopy, gels were immersed in liquid N2 and fractured.REGULATION OF SMOOTH MUSCLE CELL INVASION | Filippov et al. 670
Immunofluorescence, proliferation, and apoptosis assays. To de-
tect proteolyzed collagen, immunofluorescence was performed on frozen
sections that were fixed in 1% paraformaldehyde, incubated overnight at
4 C with mAb HUI77 (100  g/ml; gift of Cell-Matrix, Inc., a subsidiary of
CancerVax Corp.), and incubated with FITC-conjugated secondary anti-
body (1:400). Bromodeoxyuridine (BrdU) incorporation was determined
after a 60-min pulse with 10  M BrdU in isolated VSMC cultures. Apop-
tosis was assessed by TUNEL assay (Fluorescein Direct Apoptag; Intergen,
Limited; [45]). Proliferative indices in the intima of remodeled carotids
were quantified by staining sections with PCNA mAb (clone PC10, Dako-
Cytomation; [45]). VSMC and macrophages were visualized, respectively,
with anti-smooth muscle  -actin mAb (clone 1A4; DakoCytomation) and
anti-Mac-2 mAb (CL8942AP; Cedarlane Laboratories Limited).
Subjacent collagenolysis and cell motility. Isolated VSMCs (5   104)
were stimulated with a PDGF/FGF-2 mixture atop a thin film of type I col-
lagen (100  g/2.2 cm2) in the absence or presence of BB-94 (3  M). After 5 d
in culture, cells were dislodged from the collagen substratum with 10 mM
EDTA, and the integrity of the underlying matrix was assessed by Coomassie
staining. Zones of cleared collagen were counted in 10 randomly selected
fields. VSMC migration atop a collagen-coated surface was assayed as described
(29). In brief, VSMC monolayers were established on a collagen substratum
whose surface was decorated with small cloning chips. When the cultures were
confluent, the cloning chips were removed, leaving a well-demarcated de-
nuded zone wherein VSMC migration could be monitored (29).
Animal model, tissue processing and morphometric analysis. All
animal protocols were approved by the University of Michigan Committee
on Use and Care of Animals. Mice were housed in the American Association
for Accreditation of Laboratory Animal Care–approved facility of the Uni-
versity of Michigan. Left common carotid arteries of MT1-MMP /  and
MT1-MMP /  littermates (n   six each) were ligated for 2 wk as described
(34). Mouse tissues were perfusion fixed with methanol-Carnoy’s fixative
(methanol/chloroform/glacial acetic acid in a 60:30:10 volume ratio). Un-
manipulated control contralateral and ligated carotids were removed, paraffin
embedded, and sectioned (5  m thick). Vessel wall elastin and collagen were
visualized with Verhoeff Van Gieson’s (Accustain Elastic Stain, Sigma-
Aldrich) or Picro-Sirius red stains, respectively (46). Groups of four consecu-
tive carotid artery tissue sections spaced at equal intervals (150  m) were
analyzed using SPOT image software (SPOT 3.4, Diagnostic Instruments).
The lumen circumference, the length of the internal elastic lamina, and ex-
ternal elastic lamina were determined as described (34) with lumen circum-
ference used to calculate the lumen area. The intima was determined as the
area defined by the luminal surface and internal elastic lamina with the me-
dial area defined by the internal elastic lamina and external elastic lamina.
For gelatin zymography, ligated carotid arteries were collected sepa-
rately, pulverized in liquid N2 and equal amounts of tissue extract protein
(10  g), and assayed as described (29).
Statistical analysis. All data, expressed as mean   SEM, in MT1-MMP / 
and MT1-MMP /  mice, were analyzed by the paired Student’s t test. Data
were considered statistically significant at P   0.05.
Online supplemental material.  Fig. S1 shows ex vivo invasive activity
of VSMCs in 3-D Matrigel. Media explants from WT, MMP-9–, or MMP-
2–null mice were embedded within a 3-D gel of Matrigel. VSMC egress
was initiated by exogenous (PDGF/FGF-2), and outgrowth into the trans-
lucent Matrigel matrix was visualized by phase contrast microscopy at 8 d.
Asterisk indicates the explant tissue, and arrowheads point at the leading
edge of the invading SMC. Online supplemental material is available at
http://www.jem.org/cgi/content/full/jem.20050607/DC1.
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